22 assets in Alpha 1-Antitrypsin Deficiency

Therapeutic assets addressing Alpha 1-Antitrypsin Deficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alpha-1-Proteinase Inhibitor Alpha 1-Antitrypsin Deficiency	Grifols Therapeutics LLC	P4	A (82)
.Alpha.-1 Protease Inhibitor Alpha 1-Antitrypsin Deficiency	Grifols Therapeutics LLC	P4	A (81)
Fazirsiran Alpha 1-Antitrypsin Deficiency	Takeda	P3	BB (66)
20-valent pneumococcal conjugate vaccine Alpha 1-Antitrypsin Deficiency	University of Alabama at Birmingham	P4	BB (65)
Rymphysia Alpha 1-Antitrypsin Deficiency	Takeda	P4	B (60)
sar447537 Alpha 1-Antitrypsin Deficiency	Sanofi	P2	B (57)
Wve-006 Alpha 1-Antitrypsin Deficiency	Wave Life Sciences USA, Inc.	P1/2	B (57)
vx-864 Alpha 1-Antitrypsin Deficiency	Vertex Pharmaceuticals Incorporated	P2	CCC (55)
Belcesiran Alpha 1-Antitrypsin Deficiency	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	P2	CCC (50)
Tsra-196 Alpha 1-Antitrypsin Deficiency	Tessera Therapeutics, Inc.	P1/2	CCC (48)
Beam-302 Alpha 1-Antitrypsin Deficiency	Beam Therapeutics Inc.	P1/2	CC (47)
vx-668 Alpha 1-Antitrypsin Deficiency	Vertex Pharmaceuticals Incorporated	P1	CC (47)
vx-634 Alpha 1-Antitrypsin Deficiency	Vertex Pharmaceuticals Incorporated	P1	CC (46)
aav8haat Alpha 1-Antitrypsin Deficiency	Weill Medical College of Cornell University	P1	CC (43)
Air-001 Alpha 1-Antitrypsin Deficiency	AIRNA Corporation	P1	CC (43)
Bmn 349 Alpha 1-Antitrypsin Deficiency	BioMarin Pharmaceutical	P1	CC (43)
kb408 Alpha 1-Antitrypsin Deficiency	Krystal Biotech, Inc.	P1	CC (43)
Yolt-202 Alpha 1-Antitrypsin Deficiency	RenJi Hospital	Early P1	C (39)
Biological Ntla-3001 Alpha 1-Antitrypsin Deficiency	Intellia Therapeutics	P1/2	NR ()
ce1226 Alpha 1-Antitrypsin Deficiency	CSL Behring	P4	NR ()
Krro-110 Alpha 1-Antitrypsin Deficiency	Korro Bio, Inc.	P1/2	NR ()